Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Foritinib |
Synonyms | |
Therapy Description |
SAF-189s is an ALK and ROS1 inhibitor that is able to penetrate the central nervous system, which potentially reduces tumor cell proliferation and tumor growth (PMID: 32918045). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Foritinib | Foritinib succinate|SAF189s|SAF 189s|SAF-189s | ALK Inhibitor 33 ROS1 Inhibitor 21 | Foritinib is an ALK and ROS1 inhibitor that is able to penetrate the central nervous system, which potentially reduces tumor cell proliferation and tumor growth (PMID: 32918045). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK rearrange | lung non-small cell carcinoma | predicted - sensitive | Foritinib | Phase Ib/II | Actionable | In a Phase I/II trial, Foritinib was well tolerated in ALK-positive non-small cell lung cancer patients, and resulted in a disease control rate (DCR) of 100% and median progression-free survival (PFS) of 33.1 mo in ALK inhibitor (ALKi)-naive and 22.1 mo in ALKi-pretreated patients in Phase I, and a DCR of 98.1% and 88.5%, and objective response rate of 92.3% and 65.4%, in ALKi-naive or crizotinib-pretreated patients, respectively, in Phase II (J Clin Oncol 40, 2022 (suppl 16; abs 9076); NCT04237805). | detail... |
ROS1 L2026M | Advanced Solid Tumor | predicted - sensitive | Foritinib | Preclinical - Biochemical | Actionable | In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 L2026M in culture (PMID: 32918045). | 32918045 |
ROS1 G2032R | Advanced Solid Tumor | predicted - sensitive | Foritinib | Preclinical - Biochemical | Actionable | In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 G2032R in culture (PMID: 32918045). | 32918045 |
ROS1 D2033N | Advanced Solid Tumor | predicted - sensitive | Foritinib | Preclinical - Biochemical | Actionable | In a preclinical study, Foritinib inhibited the kinase activity of a transformed cell line expressing ROS1 D2033N in culture (PMID: 32918045). | 32918045 |
ROS1 S1986F | Advanced Solid Tumor | predicted - sensitive | Foritinib | Preclinical - Biochemical | Actionable | In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 S1986F in culture (PMID: 32918045). | 32918045 |
ROS1 S1986Y | Advanced Solid Tumor | predicted - sensitive | Foritinib | Preclinical - Biochemical | Actionable | In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 S1986Y in culture (PMID: 32918045). | 32918045 |
ROS1 rearrange | lung non-small cell carcinoma | sensitive | Foritinib | Phase II | Actionable | In a Phase II trial, Foritinib treatment led to an 89% (65/73, 65 partial responses (PR)) objective response rate (ORR), median duration of response (mDOR) of 20.7 mo, and median progression-free survival (mPFS) of 22.1 mo in ROS1 inhibitor-naive non-small cell lung cancer patients harboring a ROS1 rearrangement, including a 92.3% (24/26) ORR in patients with CNS lesions, and a 40% (10/25, 10 PR) ORR, mDOR of 7.0 mo, and mPFS of 5.5 mo in patients who received prior crizotinib (PMID: 39059398; NCT04237805). | 39059398 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|